ROBERT CLUCK: Open Payments
NPI 1992395966 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$551 in 29 payments from 9 companies in 2025. Trend: 2023 $895 · 2024 $607 · 2025 $551
Food & beverage: $551
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $189 |
| ABBVIE INC. | 8 | $146 |
| PFIZER INC. | 3 | $49 |
| Dexcom, Inc. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Novo Nordisk Inc | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| SANOFI-AVENTIS U.S. LLC | 1 | $16 |
Products named: BREZTRI, UBRELVY, QULIPTA, FARXIGA, Dexcom G6 Transmitter, CAPLYTA, AIRSUPRA, PREVNAR 20.
Industry payments across AR — which companies pay providers there.
